Focus: Protara Therapeutics is a public biotech company focused on cell and gene therapy platforms, headquartered in New York with a lean operational footprint.
Profile data last refreshed 9h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Protara is a cash-backed early-stage cell therapy play suitable for scientists and early-career professionals willing to trade job security for modality expertise, but minimal hiring and no near-term commercial catalysts limit career acceleration.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Protara Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Protara Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Assenagon Asset Management S.A. Sells 507,667 Shares of Protara Therapeutics, Inc. $TARA MarketBeat
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) - TradingView
Protara Therapeutics, Inc. Actuals & Estimates (NASDAQ:TARA) TradingView
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA - MarketBeat
Dimensional Fund Advisors LP Grows Stock Holdings in Protara Therapeutics, Inc. $TARA MarketBeat
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript - GuruFocus
Protara Therapeutics Inc Lymphatic Malformations KOL Webinar Transcript GuruFocus
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com - Investing.com South Africa
Form 8K Protara Therapeutics Inc For: 11 August By Investing.com Investing.com South Africa
Is Protara Therapeutics Inc (TARA) Positioned for Growth After Q - GuruFocus
Is Protara Therapeutics Inc (TARA) Positioned for Growth After Q GuruFocus
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo